Literature DB >> 2933109

Monoaminergic involvement in the pharmacological actions of buspirone.

P Skolnick, B A Weissman, M B Youdim.   

Abstract

Buspirone, MJ-13805 and MJ-13653 did not produce a '5-hydroxytryptamine (5-HT) syndrome' in rats at doses up to 20 mg kg-1. These drugs were very weak 5-HT uptake blockers (IC50 much greater than 10 microM) compared to drugs such as chlorimipramine. These drugs did not inhibit either monoamine oxidase (MAO)-A or MAO-B. The Ki values for these agents as inhibitors of [3H]-5-HT and [3H]-ketanserin binding to rat frontal cortex or hippocampal membranes were in the microM range, well above the brain concentrations achieved after an oral dose of 25 mg kg-1. Parenterally administered buspirone blocked apomorphine-induced stereotypy, inhibited the 5-HT syndrome elicited by 5-methoxy-N,N-dimethyltryptamine, and delayed the onset of p-chloroamphetamine induced behaviours.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2933109      PMCID: PMC1916732          DOI: 10.1111/j.1476-5381.1985.tb08940.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats.

Authors:  D M Kuhn; W A Wolf; M B Youdim
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

2.  Buspirone: effects on central monoaminergic transmission--possible relevance to animal experimental and clinical findings.

Authors:  S Hjorth; A Carlsson
Journal:  Eur J Pharmacol       Date:  1982-09-24       Impact factor: 4.432

Review 3.  An animal behavior model for studying central serotonergic synapses.

Authors:  B L Jacobs
Journal:  Life Sci       Date:  1976-09-15       Impact factor: 5.037

4.  [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role.

Authors:  J E Leysen; C J Niemegeers; J M Van Nueten; P M Laduron
Journal:  Mol Pharmacol       Date:  1982-03       Impact factor: 4.436

5.  Ca2+-guanine nucleotide interactions in brain membranes. I. Modulation of central 5-hydroxytryptamine receptors in the rat.

Authors:  M Mallat; M Hamon
Journal:  J Neurochem       Date:  1982-01       Impact factor: 5.372

6.  Benzodiazepines: behavioral and neurochemical mechanisms.

Authors:  L Stein; J D Belluzzi; C D Wise
Journal:  Am J Psychiatry       Date:  1977-06       Impact factor: 18.112

7.  Effect of a specific 5-HT uptake inhibitor, citalopram (Lu 10-171), on 3H-5-HT uptake in rat brain synaptosomes in vitro.

Authors:  J Hyttel
Journal:  Psychopharmacology (Berl)       Date:  1978-12-15       Impact factor: 4.530

8.  Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.

Authors:  D G Grahame-Smith
Journal:  J Neurochem       Date:  1971-06       Impact factor: 5.372

9.  The comparative efficacy of buspirone and diazepam in the treatment of anxiety.

Authors:  H L Goldberg; R J Finnerty
Journal:  Am J Psychiatry       Date:  1979-09       Impact factor: 18.112

10.  Specificity of a rat behavioral model for serotonin receptor activation.

Authors:  R S Sloviter; E G Drust; J D Connor
Journal:  J Pharmacol Exp Ther       Date:  1978-08       Impact factor: 4.030

View more
  7 in total

1.  Buspirone impairment of performance of passive avoidance and spatial learning tasks in the rat.

Authors:  M J Rowan; W K Cullen; B Moulton
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Quantitative autoradiographic distribution and pharmacological characterization of (3H)buspirone binding to sections from rat, bovine and marmoset brain.

Authors:  G Brüning; P Kaulen; U Schneider; H G Baumgarten
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

3.  Blockade of dopamine receptors explains the lack of 5-HT stereotypy on treatment with the putative 5-HT1A agonist LY165163.

Authors:  T P Donohoe; P H Hutson; G Curzon
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Serotonin does not mediate anxiolytic effects of buspirone in the fear-potentiated startle paradigm: comparison with 8-OH-DPAT and ipsapirone.

Authors:  M Davis; J V Cassella; J H Kehne
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Effect of acute administration of the 5-HT1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover.

Authors:  M Ballarín; A Carceller; X Guitart
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

6.  Behavioral and neurochemical effects of the serotonin (5-HT)1A receptor ligand spiroxatrine.

Authors:  J E Barrett; S M Hoffmann; S N Olmstead; M J Foust; C Harrod; B A Weissman
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 7.  Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.

Authors:  K L Goa; A Ward
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.